These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

251 related items for PubMed ID: 18729193

  • 1. CCAAT/enhancer binding protein-alpha polymorphisms occur more frequently than mutations in acute myeloid leukemia and exist across all cytogenetic risk groups and leukemia subtypes.
    Leecharendkeat A, Tocharoentanaphol C, Auewarakul CU.
    Int J Cancer; 2008 Nov 15; 123(10):2321-6. PubMed ID: 18729193
    [Abstract] [Full Text] [Related]

  • 2. Characterization of CEBPA Mutations and Polymorphisms and their Prognostic Relevance in De Novo Acute Myeloid Leukemia Patients.
    Sarojam S, Raveendran S, Vijay S, Sreedharan J, Narayanan G, Sreedharan H.
    Asian Pac J Cancer Prev; 2015 Nov 15; 16(9):3785-92. PubMed ID: 25987038
    [Abstract] [Full Text] [Related]

  • 3. Molecular evaluation of CEBPA gene mutation in normal karyotype acute myeloid leukemia: a comparison of two methods and report of novel CEBPA mutations from Indian acute myeloid leukemia patients.
    Ahmad F, Rajput S, Mandava S, Das BR.
    Genet Test Mol Biomarkers; 2012 Jul 15; 16(7):707-15. PubMed ID: 22731647
    [Abstract] [Full Text] [Related]

  • 4. Prognostic significance of CEBPA mutations in a large cohort of younger adult patients with acute myeloid leukemia: impact of double CEBPA mutations and the interaction with FLT3 and NPM1 mutations.
    Green CL, Koo KK, Hills RK, Burnett AK, Linch DC, Gale RE.
    J Clin Oncol; 2010 Jun 01; 28(16):2739-47. PubMed ID: 20439648
    [Abstract] [Full Text] [Related]

  • 5. Risk assessment in patients with acute myeloid leukemia and a normal karyotype.
    Bienz M, Ludwig M, Leibundgut EO, Mueller BU, Ratschiller D, Solenthaler M, Fey MF, Pabst T.
    Clin Cancer Res; 2005 Feb 15; 11(4):1416-24. PubMed ID: 15746041
    [Abstract] [Full Text] [Related]

  • 6. CEBPA gene mutations in Egyptian acute myeloid leukemia patients: impact on prognosis.
    Awad MM, Aladle DA, Abousamra NK, Elghannam DM, Fawzy IM.
    Hematology; 2013 Mar 15; 18(2):61-8. PubMed ID: 22990006
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Prognostic significance of CEBPA mutations and BAALC expression in acute myeloid leukemia Egyptian patients with normal karyotype.
    El-Sharnouby JA, Ahmed LM, Taha AM, Kamal O.
    Egypt J Immunol; 2008 Mar 15; 15(1):131-43. PubMed ID: 20306678
    [Abstract] [Full Text] [Related]

  • 9. Molecular genetic tests for FLT3, NPM1, and CEBPA in acute myeloid leukemia.
    Zhang Q, Bai S, Vance GH.
    Methods Mol Biol; 2013 Mar 15; 999():105-21. PubMed ID: 23666693
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. A clinical grade sequencing-based assay for CEBPA mutation testing: report of a large series of myeloid neoplasms.
    Behdad A, Weigelin HC, Elenitoba-Johnson KS, Betz BL.
    J Mol Diagn; 2015 Jan 15; 17(1):76-84. PubMed ID: 25468431
    [Abstract] [Full Text] [Related]

  • 12. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia.
    Schlenk RF, Döhner K, Krauter J, Fröhling S, Corbacioglu A, Bullinger L, Habdank M, Späth D, Morgan M, Benner A, Schlegelberger B, Heil G, Ganser A, Döhner H, German-Austrian Acute Myeloid Leukemia Study Group.
    N Engl J Med; 2008 May 01; 358(18):1909-18. PubMed ID: 18450602
    [Abstract] [Full Text] [Related]

  • 13. GATA2 mutations in patients with acute myeloid leukemia-paired samples analyses show that the mutation is unstable during disease evolution.
    Hou HA, Lin YC, Kuo YY, Chou WC, Lin CC, Liu CY, Chen CY, Lin LI, Tseng MH, Huang CF, Chiang YC, Liu MC, Liu CW, Tang JL, Yao M, Huang SY, Ko BS, Hsu SC, Wu SJ, Tsay W, Chen YC, Tien HF.
    Ann Hematol; 2015 Feb 01; 94(2):211-21. PubMed ID: 25241285
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Combined testing for CCAAT/enhancer-binding protein alpha (CEBPA) mutations and promoter methylation in acute myeloid leukemia demonstrates shared phenotypic features.
    Szankasi P, Ho AK, Bahler DW, Efimova O, Kelley TW.
    Leuk Res; 2011 Feb 01; 35(2):200-7. PubMed ID: 20970189
    [Abstract] [Full Text] [Related]

  • 16. CEBPA polymorphisms and mutations in patients with acute myeloid leukemia, myelodysplastic syndrome, multiple myeloma and non-Hodgkin's lymphoma.
    Fuchs O, Provaznikova D, Kocova M, Kostecka A, Cvekova P, Neuwirtova R, Kobylka P, Cermak J, Brezinova J, Schwarz J, Markova J, Salaj P, Klamova H, Maaloufova J, Lemez P, Novakova L, Benesova K.
    Blood Cells Mol Dis; 2008 Feb 01; 40(3):401-5. PubMed ID: 18182175
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. [CEBPA gene mutation analysis in acute myeloid leukemia].
    Han C, Lin D, Ai XF, Wang F, Sun HY, Wang M, Mi YC, Wang JX, Ru K.
    Zhonghua Xue Ye Xue Za Zhi; 2013 Jul 01; 34(7):566-71. PubMed ID: 23906447
    [Abstract] [Full Text] [Related]

  • 20. Expression of myeloperoxidase and gene mutations in AML patients with normal karyotype: double CEBPA mutations are associated with high percentage of MPO positivity in leukemic blasts.
    Tominaga-Sato S, Tsushima H, Ando K, Itonaga H, Imaizumi Y, Imanishi D, Iwanaga M, Taguchi J, Fukushima T, Yoshida S, Hata T, Moriuchi Y, Kuriyama K, Mano H, Tomonaga M, Miyazaki Y.
    Int J Hematol; 2011 Jul 01; 94(1):81-89. PubMed ID: 21674360
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.